A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants of study V48P7 and long-term evaluation of immunogenicity up to 5 years after first booster immunization

ovartis Vaccines and Diagnostics GmbH & Co. KG0 个研究点目标入组 389 人开始时间: 2006年5月23日最近更新: 2015年7月10日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 389

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- healthy subjects who/whose parents/legal representative signed informed consent prior to study entry
•- subjects who have completed study V48P7
•- subjects who are in good health as determined by medical history, physical examination, and clinical judgment of the investigator
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•- subjects with acute disease at the day of booster immunization (acute disease means moderate or severe illness with or without fever. All vaccines can be administered to subjects with minor illness such as mild diarrhea or mild upper respiratory tract infection with oral temperature < 38.0°C.)*
•- subjects in whom a general decrease in resistance might be expected, e.g. those who have recently sustained major injury or undergone recent major surgical operations, are undernourished, or have disorders involving a decreased immune response
•- subjects:
•a) with organic brain disturbances, including seizure disorders*
•b) with progressive neurological disorders
•c) who have suffered febrile or afebrile convulsions*
•d) with major congenital defects
•e) with serious chronic illness (such as insulin dependent diabetes, cancer, autoimmune diseases)
•f) with evidence of hypersensitivity to the study vaccine or chemically related substances in their medical history*
•- subjects being treated with:
•a) immunosuppressants or systemic corticosteroids within the past 4 weeks or during the study period, except short term use of topic corticosteroids
•b) immunoglobulins, whole blood or plasma derivates up to 3 months before enrollment
•- subjects who have received another vaccine within 4 weeks before the administration of the study vaccine *
•- subjects enrolled in another investigational, clinical study at the same time or within the last 3 months
•- women who are pregnant (in case of uncertainty, pregnancy should be excluded by a pregnancy test) *
•- women of childbearing age who refuse to use an effective method of birth control (abstinence, oral or injected or implanted hormonal contraceptive, diaphragm or condom with spermicidal agent, intrauterine device) beginning 28 days before study entry and continuing through 28 days after the immunization*
•* Only apply to subjects receiving booster immunization

研究者

发起方

ovartis Vaccines and Diagnostics GmbH & Co. KG

相似试验

进行中（未招募）

1 期

An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAX? at minimum release specification approaching expiry potency in subjects =50 years oldot applicable_Healthy volunteers_Up to 50 years of age

EUCTR2007-006532-66-FRSanofi Pasteur MSD SNC

进行中（未招募）

1 期

ong term immunogenicity up to 15 years after the first booster immunization with GSK Biologicals’Encepur Adults in adults who received 1 of 3 different primary vaccination schedules.

EUCTR2017-001356-59-CZGlaxoSmithKline Biologicals200

进行中（未招募）

1 期

A phase IV clincal study to evaluate antibody responses through 6 to 10 yearsafter after first booster with TBE vaccine.

EUCTR2011-003255-19-CZGlaxoSmithKline Biologicals SA

进行中（未招募）

不适用

Evaluation of the long-term persistence of hepatitis A antibodies in healthy adults who were vaccinated 21-25 years earlier with GlaxoSmithKline (GSK) Biologicals’ hepatitis A vaccine, Havrix®.Healthy volunteers (Vaccination against hepatitis A in healthy adults)MedDRA version: 16.1Level: LLTClassification code 10052551Term: Hepatitis A virusSystem Organ Class: 100000004848

EUCTR2013-001918-15-BEGlaxoSmithKline Biologicals

进行中（未招募）

不适用

A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 59 years) and ‘Older Adults’ (aged 60 years or older).

EUCTR2010-019532-12-GBCSL Limited